What is Biostate Ai?
Biostate Ai operates at the intersection of advanced machine learning and biological research. The company is dedicated to developing generative AI architectures capable of modeling the complex, temporal variations inherent in human biology. By recognizing that biological entities are dynamic systems that evolve over time, the firm aims to provide predictive insights that could fundamentally transform personalized medicine and therapeutic development. Their market position is defined by a commitment to high-fidelity data processing and the application of HardTech principles to solve fundamental health challenges.
How much funding has Biostate Ai raised?
Biostate Ai has raised a total of $16M across 2 funding rounds:
Other Financing Round
$4M
Series A
$12M
Other Financing Round (2024): $4M with participation from Vision Plus, Matter Venture Partners MVP, and Catapult VC
Series A (2025): $12M led by Mana Ventures, Vision Plus Capital, Accel, Info Edge Ventures, Gaingels, Catapult Ventures, and Matter Venture Partners MVP
Key Investors in Biostate Ai
Accel
Accel is a global venture capital firm that partners with exceptional teams from the inception of their ideas through all phases of private company growth.
Vision Plus Capital
Founded by Alibaba co-founder Wu Yongming, this firm specializes in hard technology, industrial manufacturing, and digital healthcare ventures.
Mana Ventures
Mana Ventures focuses on investing in advanced technologies that redefine industries, including artificial intelligence, software, and biotech.
What's next for Biostate Ai?
Following this major enterprise-level funding, Biostate Ai is expected to prioritize the expansion of its technical infrastructure and the recruitment of specialized talent in bioinformatics and AI engineering. The strategic roadmap likely includes deepening partnerships with clinical research organizations to validate their generative models against real-world patient data. As the company moves beyond its Series A phase, the focus will shift toward achieving product-market fit in high-impact areas such as drug discovery and longitudinal health monitoring. Investors will be looking for measurable progress in model accuracy and the successful deployment of pilot programs that demonstrate the tangible benefits of their AI-driven health insights.
See full Biostate Ai company page
